Andrea Calvo

Andrea Calvo

Associate Professor of Neurology

Andrea Calvo is currently Associate Professor of Neurology at the Department of Neurosciences ‘Rita Levi Montalcini’ of the University of Turin. He has been working at Turin ALS Expert Centre since 1997, as clinical-coordinator. He is the Chair of the Italian Motoneuron Diseases Study Group of the Italian Society of Neurology (SIN) and Co-chair of EAN Scientific Panel for ALS and FTD. Since 1997 he has been a researcher in the neurological field, with particular interest in ALS and other neuromuscular diseases; his scientific production is characterized by epidemiological, clinical genetics, neuroimaging and clinical trials, with more than 170 papers in peer reviewed international journals (H Scopus index 50).

Connect
Connect trials
Recruiting
Phase iii

PHOENIX trial

Industry trial

Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.

Read more
Recruiting
Phase iii

ADORE Trial

Industry trial

Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).

Read more
Recruiting
Phase iii

COURAGE-ALS Trial

Industry trial

In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.

Read more
Active
Phase ii

APL2-ALS-206 Trial

Industry trial

In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.

Read more
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial

In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.

Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial

This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.

Read more